A Phase 3 interventional study of MenACYW conjugate vaccine and MenACYW conjugate vaccine in Meningococcal Immunisation and Healthy Volunteers, sponsored by Sanofi Pasteur, a Sanofi Company. Completed at 45 sites in 6 countries. Open to participants aged 6 Months to 14 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by Sanofi Pasteur, a Sanofi Company (part of Sanofi) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study was conducted to support a 2-dose series (1+1 vaccination schedule) for immunization of individuals from 6 months of age. The study was designed to evaluate the non-inferiority of the immunological response of MenACYW conjugate vaccine to Nimenrix® after the completion of the 2-dose series (1+1 vaccination schedule), with the first dose (priming dose) being given at 6-7 months of age to MenACWY- naïve healthy infants and the second dose (booster dose) given at 12-13 months of age. This study also described additional immunogenicity parameters and safety of MenACYW conjugate vaccine and Nimenrix® in the same population of participants.
The study duration would be approximately 7 to 8.5 months (at least 7 months per participant).
Sanofi Pasteur, a Sanofi Company is the lead sponsor of 374 studies on the registry; 4 are open to participants now.
Of its 94 completed or terminated interventional studies of FDA-regulated products, 73 (78%) have results posted.
First submitted after Sanofi Pasteur became part of Sanofi.
Counted across the registry records on this site, refreshed daily.
The criteria were revised on the registry on Oct 7, 2026. See what changed
Inclusion Criteria:
Exclusion Criteria: Participants were excluded from the study if any of the following criteria apply:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received the MenACYW conjugate vaccine in a 1+1 dosing schedule (2-dose series). The priming dose (Dose 1) was administered at 6-7 months of age on Day 1, and the booster dose (Dose 2) was administered at 12-13 months of age at Month 6. Each dose consisted of 0.5 milliliter (mL) intramuscular (IM) injection.
Biological: MenACYW conjugate vaccine
Participants received Nimenrix® vaccine as a 1+1 dosing schedule (2-dose series). The priming dose (Dose 1) was administered at 6-7 months of age on Day 1 and, the booster dose (Dose 2) was administered at 12-13 months of age at Month 6. Each dose consisted of 0.5 mL IM injection.
Biological: MenACYW conjugate vaccine
Pharmaceutical form:Solution for injection (in a single-dose vial)-Route of administration:Intramuscular (IM) injection
Also known as: MenQuadfi®
Pharmaceutical form:Solution for injection (powder or cake in a single dose glass vial and a clear and colourless solvent in a pre filled syringe for reconstitution-Route of administration:Intramuscular (IM) injection
Also known as: Nimenrix®
Geometric Mean Titers (GMTs) Against Meningococcal Serogroups A, C, W, and Y as Measured by Serum Bactericidal Assays Using Human Complement (hSBA) 30 Days After Dose 2 (Booster Dose)
Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the hSBA and the results were expressed as geometric mean titers.
Time frame: At Month 7 (30 days post-dose 2)
Percentage of Participants With Vaccine Seroresponse as Measured By Serum Bactericidal Assay Using Human Complement Against Meningococcal Serogroups A, C, W and Y 30 Days After Dose 2 (Booster Dose) Compared to Pre-Dose 1 (Priming Dose)
Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the hSBA. hSBA vaccine seroresponse was defined for a participant with a pre-vaccination (pre-dose 1: priming dose) titer \<1:8, as a post-vaccination (post-dose 2: booster dose) titer of \>=1:16 and for a participant with a pre-vaccination (pre-dose 1: priming dose) titer \>=1:8, as a post-vaccination (post-dose 2: booster dose) titer that is at least 4-fold greater than the pre-vaccination (pre-dose 1: priming dose) titer. Percentages are rounded to the nearest tenth.
Time frame: Day 1 (pre-dose 1) and Month 7 (30 days post-dose 2)
Percentage of Participants With Serum Bactericidal Assay Using Human Complement Antibody Titers >=1:8 Against Meningococcal Serogroups A, C, W, and Y 30 Days After Dose 1 (Priming Dose)
Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the hSBA. The percentage of participants with antibody titers \>=1:8 were assessed. Percentages are rounded to the nearest tenth.
Time frame: Day 31 (30 days post-dose 1)
Geometric Mean Titers Against Meningococcal Serogroups A, C, W, and Y as Measured by Serum Bactericidal Assay Using Human Complement Before Dose 1 and 30 Days After Dose 1 (Priming Dose)
Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the hSBA and the results were expressed as geometric mean titers.
Time frame: Day 1 (pre-dose 1) and Day 31 (30 days post-dose 1)
Percentage of Participants With Serum Bactericidal Assay Using Human Complement Antibody Titers >=1:4 and >=1:8 Before Dose 1 (Pre-dose) and 30 Days After Dose 1 (Priming Dose)
Functional meningococcal antibody activity against serogroups A, C, Y, and W was measured in a serum bactericidal assay utilizing the hSBA. Participants with hSBA titers \>= 1:4 and \>= 1:8 were analyzed. Percentages are rounded to the nearest tenth.
Time frame: Day 1 (pre-dose 1) and Day 31 (30 days post-dose 1)
Percentage of Participants With >=4-Fold Rise in Serum Bactericidal Assay Using Human Complement Antibody Titers From Before Dose 1 and 30 Days After Dose 1 (Priming Dose)
Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the hSBA. Participants with hSBA titers \>= 4-fold increase from baseline (pre-vaccination) were analyzed. Percentages are rounded to the nearest tenth.
Time frame: Day 1 (pre-dose 1) and Day 31 (30 days post-dose 1)
Percentage of Participants With Vaccine Seroresponse as Measured by Serum Bactericidal Assay Using Human Complement Against Meningococcal Serogroups A, C, W and Y 30 Days After Dose 1 Compared to Pre-Dose 1 (Priming Dose)
Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the hSBA. hSBA vaccine seroresponse was defined for a participant with a pre-vaccination (pre-dose 1: priming dose) titer \<1:8, as a post-vaccination (post-dose 1: priming dose) titer of \>=1:16 and for a participant with a pre-vaccination (pre-dose 1: priming dose) titer \>=1:8, as a post-vaccination (post-dose 1: priming dose) titer that is at least 4-fold greater than the pre-vaccination (pre-dose 1: priming dose) titer. Percentages are rounded to the nearest tenth.
Time frame: Day 1 (pre-dose 1) and Day 31 (30 days post-dose 1)
Geometric Mean Titers Against Meningococcal Serogroups A, C, W, and Y as Measured by Serum Bactericidal Assay Using Human Complement Before Dose 2 and 30 Days After Dose 2 (Booster Dose)
Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the hSBA and the results were expressed as geometric mean titers.
Time frame: Month 6 (pre-dose 2) and Month 7 (30 days post-dose 2)
Percentage of Participants With Serum Bactericidal Assay Using Human Complement Antibody Titers >=1:4 and >=1:8 Before Dose 2 and 30 Days After Dose 2 (Booster Dose)
Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the hSBA. Participants with hSBA titers \>= 1:4 and \>= 1:8 were analyzed. Percentages are rounded to the nearest tenth.
Time frame: Month 6 (pre-dose 2) and Month 7 (30 days post-dose 2)
Percentage of Participants With >=4-Fold Rise in Serum Bactericidal Assay Using Human Complement Antibody Titers From Before Dose 2 and 30 Days After Dose 2 (Booster Dose)
Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay that utilized hSBA. Participants with hSBA titers \>= 4-fold increase from dose 2 (pre-booster dose) were analyzed. Percentages are rounded to the nearest tenth.
Time frame: Month 6 (pre-dose 2) and Month 7 (30 days post-dose 2)
Percentage of Participants With Vaccine Seroresponse as Measured by Serum Bactericidal Assay Using Human Complement Against Meningococcal Serogroups A, C, W, and Y 30 Days After Dose 2 Compared to Pre-Dose 2 (Booster Dose)
Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the hSBA. hSBA vaccine seroresponse was defined for a participant with a pre-vaccination (pre-dose 2: booster dose) titer \<1:8, as a post-vaccination (post-dose 2: booster dose) titer of \>=1:16 and for a participant with a pre-vaccination titer (pre-dose 2: booster dose) \>=1:8, as a post-vaccination titer (post-dose 2: booster dose) that is at least 4-fold greater than the pre-vaccination titer (pre-dose 2: booster dose). Percentages are rounded to the nearest tenth. Percentages are rounded to the nearest tenth.
Time frame: Month 6 (pre-dose 2) and Month 7 (30 days post-dose 2)
Geometric Mean Titers Against Meningococcal Serogroups A, C, W, and Y as Measured by Serum Bactericidal Assay Using Human Complement Before Dose 1 (Priming Dose) and 30 Days After Dose 2 (Booster Dose)
Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the hSBA and the results were expressed as geometric mean titers.
Time frame: Day 1 (pre-dose 1) and Month 7 (30 days post-dose 2)
Percentage of Participants With Serum Bactericidal Assay Using Human Complement Antibody Titers >=1:4 and >=1:8 Before Dose 1 (Priming Dose) and 30 Days After Dose 2 (Booster Dose)
Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the hSBA. Participants with hSBA titers \>= 1:4 and \>= 1:8 were analyzed. Percentages are rounded to the nearest tenth.
Time frame: Day 1 (pre-dose 1) and Month 7 (30 days post-dose 2)
Percentage of Participants With >=4-Fold Rise in Serum Bactericidal Assay Using Human Complement Antibody Titers From Before Dose (Priming Dose) and 30 Days After Dose 2 (Booster Dose)
Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the hSBA. Participants with hSBA titers \>= 4-fold increase from baseline (pre-vaccination) were analyzed. Percentages are rounded to the nearest tenth.
Time frame: Day 1 (pre-dose 1) and Month 7 (30 days post-dose 2)
Geometric Mean Titers Against Meningococcal Serogroups A, C, W, and Y as Measured by Serum Bactericidal Assays Using Baby Rabbit Complement (rSBA) Before Dose 1 and 30 Days After Dose 1 (Priming Dose)
Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the rSBA and the results were expressed as geometric mean titers.
Time frame: Day 1 (pre-dose 1) and Day 31 (30 days post-dose 1)
Percentage of Participants With Serum Bactericidal Assays Using Baby Rabbit Complement Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, W, and Y Before Dose 1 and 30 Days After Dose 1 (Priming Dose)
Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the rSBA. Participants with rSBA titers \>= 1:8 and \>= 1:128 were analyzed. Percentages are rounded to the nearest tenth.
Time frame: Day 1 (pre-dose 1) and Day 31 (30 days post-dose 1)
Percentage of Participants With >=4-Fold Rise in Serum Bactericidal Assays Using Baby Rabbit Complement Titers From Before Dose 1 and 30 Days After Dose 1 (Priming Dose)
Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the rSBA. Participants with rSBA titers \>= 4-fold increase from baseline (pre-vaccination) were analyzed. Percentages are rounded to the nearest tenth.
Time frame: Day 1 (pre-dose 1) and Day 31 (30 days post-dose 1)
Percentage of Participants With Vaccine Seroresponse as Measured by Serum Bactericidal Assays Using Baby Rabbit Complement 30 Days After Dose 1 Compared and Pre-Dose 1 (Priming Dose)
Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the rSBA. rSBA vaccine seroresponse was defined for a participant with a pre-vaccination (pre-dose 1: priming dose) titer \<1:8, as a post-vaccination titer (post-dose 2: priming dose) of \>=1:32 and for a participant with a pre-vaccination titer (pre-dose 1: priming dose) \>=1:8, as a post-vaccination (post-dose 2: priming dose) titer that is at least 4-fold greater than the pre-vaccination (pre-dose 1: priming dose) titer. Percentages are rounded to the nearest tenth. Percentages are rounded to the nearest tenth.
Time frame: Day 1 (pre-dose 1) and Day 31 (30 days post-dose 1)
Geometric Mean Titers Against Meningococcal Serogroups A, C, W, and Y Measured by Serum Bactericidal Assays Using Baby Rabbit Complement Before Dose 2 and 30 Days After Dose 2 (Booster Dose)
Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the rSBA and the results were expressed as geometric mean titers.
Time frame: Month 6 (pre-dose 2) and Month 7 (30 days post-dose 2)
Percentage of Participants With Serum Bactericidal Assays Using Baby Rabbit Complement Antibody Titers >=1:8 and >=1:128 Before Dose 2 and 30 Days After Dose 2 (Booster Dose)
Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the rSBA. Participants with rSBA titers \>= 1:8 and \>= 1:128 were analyzed. Percentages are rounded to the nearest tenth.
Time frame: Month 6 (pre-dose 2) and Month 7 (30 days post-dose 2)
Percentage of Participants With >=4-Fold Rise in Serum Bactericidal Assays Using Baby Rabbit Complement Titers From Before Dose 2 and 30 Days After Dose 2 (Booster Dose)
Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the rSBA. Participants with rSBA titers \>= 4-fold increase from dose 2 (pre-booster dose) were analyzed. Percentages are rounded to the nearest tenth.
Time frame: Month 6 (pre-dose 2) and Month 7 (30 days post-dose 2)
Percentage of Participants With Vaccine Seroresponse as Measured by Serum Bactericidal Assays Using Baby Rabbit Complement 30 Days After Dose 2 Compared to Pre-Dose 2 (Booster Dose)
Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the rSBA. rSBA vaccine seroresponse was defined for a participant with a pre-vaccination (pre-dose 2: booster dose) titer \<1:8 as a post-vaccination (post-dose 2: booster dose) titer of \>=1:32 and for a participant with a pre-vaccination (pre-dose 2: booster dose) titer \>=1:8 as a post-vaccination (post-dose 2: booster dose) titer that is at least 4-fold greater than the pre-vaccination (pre-dose 2: booster dose) titer. Percentages are rounded to the nearest tenth.
Time frame: Month 6 (pre-dose 2) and Month 7 (30 days post-dose 2)
Geometric Mean Titers Against Meningococcal Serogroups A, C, W, and Y Measured by Serum Bactericidal Assays Using Baby Rabbit Complement Before Dose 1 (Priming Dose) and 30 Days After Dose 2 (Booster Dose)
Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the rSBA and the results were expressed as geometric mean titers.
Time frame: Day 1 (pre-dose 1) and Month 7 (30 days post-dose 2)
Percentage of Participants With Serum Bactericidal Assays Using Baby Rabbit Complement Antibody Titers >=1:8 and >=1:128 Before Dose 1 (Priming Dose) and 30 Days After Dose 2 (Booster Dose)
Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the rSBA. Participants with rSBA titers \>= 1:8 and \>= 1:128 were analyzed. Percentages are rounded to the nearest tenth.
Time frame: Day 1 (pre-dose 1) and Month 7 (30 days post-dose 2)
Percentage of Participants With >=4-Fold Rise in Serum Bactericidal Assays Using Baby Rabbit Complement Titers From Before Dose (Priming Dose) and 30 Days After Dose 2 (Booster Dose)
Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the rSBA. Participants with rSBA titers \>= 4-fold increase from baseline (pre-vaccination) were analyzed. Percentages are rounded to the nearest tenth.
Time frame: Day 1 (pre-dose 1) and Month 7 (30 days post-dose 2)
Percentage of Participants With Vaccine Seroresponse as Measured by Serum Bactericidal Assays Using Baby Rabbit Complement 30 Days After Dose 2 (Booster Dose) Compared to Pre-Dose 1 (Priming Dose)
Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the rSBA. rSBA vaccine seroresponse was defined for a participant with a pre-vaccination (pre-dose 1: priming dose) titer \<1:8, as a post-vaccination (post-dose 2: booster dose) titer of \>=1:32 and for a participant with a pre-vaccination (pre-dose 1: priming dose) titer \>=1:8, as a post-vaccination (post-dose 2: booster dose) titer that is at least 4-fold greater than the pre-vaccination (pre-dose 1: priming dose) titer. Percentages are rounded to the nearest tenth.
Time frame: Day 1 (pre-dose 1) and Month 7 (30 days post-dose 2)
Number of Participants With Immediate Unsolicited Systemic Adverse Events (AEs)
An unsolicited AE was an observed AE that did not fulfill the conditions of solicited reactions, i.e., pre-listed in the case report form (CRF) in terms of diagnosis and onset window post-vaccination.
Time frame: Up to 30 minutes after each vaccination (Dose 1 on Day 1 and Dose 2 on Month 6)
Number of Participants With Solicited Injection Site Reactions and Systemic Reactions
A solicited reaction was an "expected" adverse reaction (AR) (sign or symptom) observed and reported under the conditions (nature and onset) pre-listed in the protocol and CRF. An injection site reaction was an AR at and around the injection site. Solicited systemic reactions were systemic AEs observed and reported under the conditions (nature and onset) pre-listed in the protocol and CRF.
Time frame: Up to 7 days after each vaccination (Dose 1 on Day 1 and Dose 2 on Month 6)
Number of Participants With Unsolicited Adverse Events
An unsolicited AE was an observed AE that did not fulfill the conditions of solicited reactions, i.e., pre-listed in the CRF in terms of diagnosis and/or onset window post-vaccination.
Time frame: Up to 30 days after each vaccination (Dose 1 on Day 1 and Dose 2 on Month 6)
Number of Participants With Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs)
An SAE was any AE that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event. An AESI (serious or non-serious) was defined as one of scientific and medical concern specific to the Sponsor's study intervention or program, for which ongoing monitoring and rapid communication by the investigator to the Sponsor could be appropriate.
Time frame: From first vaccination (Day 1) up to 30 days post last vaccination, approximately 7 months
This study was conducted at 47 centers in 6 countries from 19 March 2024 to 14 November 2025.
| Milestone | Group 1: MenACYW Conjugate Vaccine | Group 2: Nimenrix® Vaccine |
|---|---|---|
| Started | 422 | 418 |
| Safety analysis set (safas) | 417 | 412 |
| Completed | 402 | 393 |
| Not completed | 20 | 25 |
| Withdrew: Lost to follow-up | 2 | 7 |
| Withdrew: Withdrawal by parent/guardian | 16 | 6 |
| Withdrew: Protocol violation | 2 | 5 |
| Withdrew: Adverse event | 0 | 6 |
| Withdrew: Visit 4 not performed as per protocol | 0 | 1 |
Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the hSBA and the results were expressed as geometric mean titers.
| titer | Group 1: MenACYW Conjugate Vaccine | Group 2: Nimenrix® Vaccine |
|---|---|---|
| Serogroup A | 170 (143 to 202) | 203 (168 to 246) |
| Serogroup C | 1112 (986 to 1253) | 302 (258 to 355) |
| Serogroup Y | 289 (259 to 323) | 268 (237 to 303) |
| Serogroup W | 275 (240 to 316) | 299 (258 to 345) |
Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the hSBA. hSBA vaccine seroresponse was defined for a participant with a pre-vaccination (pre-dose 1: priming dose) titer \<1:8, as a post-vaccination (post-dose 2: booster dose) titer of \>=1:16 and for a participant with a pre-vaccination (pre-dose 1: priming dose) titer \>=1:8, as a post-vaccination (post-dose 2: booster dose) titer that is at least 4-fold greater than the pre-vaccination (pre-dose 1: priming dose) titer. Percentages are rounded to the nearest tenth.
| percentage of participants | Group 1: MenACYW Conjugate Vaccine | Group 2: Nimenrix® Vaccine |
|---|---|---|
| Serogroup A | 80.4 (75.2 to 84.9) | 78.1 (72.5 to 83.0) |
| Serogroup C | 98.9 (96.8 to 99.8) | 96.2 (93.1 to 98.2) |
| Serogroup Y | 99.0 (97.0 to 99.8) | 98.5 (96.3 to 99.6) |
| Serogroup W | 97.6 (95.0 to 99.0) | 97.4 (94.8 to 99.0) |
Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the hSBA. The percentage of participants with antibody titers \>=1:8 were assessed. Percentages are rounded to the nearest tenth.
| percentage of participants | Group 1: MenACYW Conjugate Vaccine | Group 2: Nimenrix® Vaccine |
|---|---|---|
| Serogroup A | 71.8 (66.9 to 76.4) | 90.0 (86.4 to 92.9) |
| Serogroup C | 99.2 (97.6 to 99.8) | 89.8 (86.2 to 92.8) |
| Serogroup Y | 72.8 (68.0 to 77.3) | 56.6 (51.3 to 61.8) |
| Serogroup W | 50.9 (45.7 to 56.2) | 24.4 (20.1 to 29.2) |
Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the hSBA and the results were expressed as geometric mean titers.
| titer | Group 1: MenACYW Conjugate Vaccine | Group 2: Nimenrix® Vaccine |
|---|---|---|
| Serogroup A: Day 1 | 7.55 (6.04 to 9.42) | 7.02 (5.64 to 8.73) |
| Serogroup A: Day 31 | 18.9 (15.8 to 22.6) | 33.6 (28.9 to 39.1) |
| Serogroup C: Day 1 | 3.12 (2.78 to 3.50) | 2.81 (2.54 to 3.11) |
| Serogroup C: Day 31 | 360 (319 to 406) | 34.7 (30.6 to 39.5) |
| Serogroup Y: Day 1 | 2.06 (2.01 to 2.10) | 2.14 (2.06 to 2.24) |
| Serogroup Y: Day 31 | 11.4 (10.1 to 12.8) | 7.88 (6.95 to 8.93) |
| Serogroup W: Day 1 | 2.19 (2.06 to 2.33) | 2.20 (2.07 to 2.32) |
| Serogroup W: Day 31 | 6.64 (5.87 to 7.52) | 3.82 (3.42 to 4.28) |
Functional meningococcal antibody activity against serogroups A, C, Y, and W was measured in a serum bactericidal assay utilizing the hSBA. Participants with hSBA titers \>= 1:4 and \>= 1:8 were analyzed. Percentages are rounded to the nearest tenth.
| percentage of participants | Group 1: MenACYW Conjugate Vaccine | Group 2: Nimenrix® Vaccine |
|---|---|---|
| Serogroup A: >=1:4; Day 1 | 39.3 (34.2 to 44.6) | 35.7 (30.7 to 41.0) |
| Serogroup A: >=1:4; Day 31 | 85.4 (81.3 to 88.8) | 95.0 (92.2 to 97.0) |
| Serogroup A: >=1:8; Day 1 | 27.5 (23.0 to 32.5) | 27.1 (22.6 to 32.1) |
| Serogroup A: >=1:8; Day 31 | 71.8 (66.9 to 76.4) | 90.0 (86.4 to 92.9) |
| Serogroup C: >=1:4; Day 1 | 19.1 (15.1 to 23.6) | 15.6 (11.9 to 19.9) |
| Serogroup C: >=1:4; Day 31 | 99.4 (98.0 to 99.9) | 93.5 (90.4 to 95.8) |
| Serogroup C: >=1:8; Day 1 | 14.5 (11.0 to 18.7) | 11.3 (8.1 to 15.1) |
| Serogroup C: >=1:8; Day 31 | 99.2 (97.6 to 99.8) | 89.8 (86.2 to 92.8) |
| Serogroup Y: >=1:4; Day 1 | 2.3 (1.0 to 4.4) | 3.7 (2.0 to 6.3) |
| Serogroup Y: >=1:4; Day 31 | 83.7 (79.5 to 87.3) | 72.8 (67.9 to 77.4) |
| Serogroup Y: >=1:8; Day 1 | 1.4 (0.5 to 3.3) | 2.9 (1.4 to 5.2) |
| Serogroup Y: >=1:8; Day 31 | 72.8 (68.0 to 77.3) | 56.6 (51.3 to 61.8) |
| Serogroup W: >=1:4; Day 1 | 3.7 (2.0 to 6.2) | 4.9 (2.9 to 7.7) |
| Serogroup W: >=1:4; Day 31 | 62.1 (56.9 to 67.0) | 39.3 (34.2 to 44.6) |
| Serogroup W: >=1:8; Day 1 | 2.3 (1.0 to 4.4) | 2.6 (1.2 to 4.8) |
| Serogroup W: >=1:8; Day 31 | 50.9 (45.7 to 56.2) | 24.4 (20.1 to 29.2) |
Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the hSBA. Participants with hSBA titers \>= 4-fold increase from baseline (pre-vaccination) were analyzed. Percentages are rounded to the nearest tenth.
| percentage of participants | Group 1: MenACYW Conjugate Vaccine | Group 2: Nimenrix® Vaccine |
|---|---|---|
| Serogroup A | 44.8 (39.5 to 50.1) | 64.6 (59.3 to 69.6) |
| Serogroup C | 96.8 (94.3 to 98.4) | 82.7 (78.3 to 86.6) |
| Serogroup Y | 71.5 (66.5 to 76.2) | 54.0 (48.6 to 59.4) |
| Serogroup W | 49.7 (44.4 to 55.1) | 24.3 (19.9 to 29.1) |
Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the hSBA. hSBA vaccine seroresponse was defined for a participant with a pre-vaccination (pre-dose 1: priming dose) titer \<1:8, as a post-vaccination (post-dose 1: priming dose) titer of \>=1:16 and for a participant with a pre-vaccination (pre-dose 1: priming dose) titer \>=1:8, as a post-vaccination (post-dose 1: priming dose) titer that is at least 4-fold greater than the pre-vaccination (pre-dose 1: priming dose) titer. Percentages are rounded to the nearest tenth.
| percentage of participants | Group 1: MenACYW Conjugate Vaccine | Group 2: Nimenrix® Vaccine |
|---|---|---|
| Serogroup A | 31.4 (26.6 to 36.6) | 55.4 (50.1 to 60.7) |
| Serogroup C | 96.5 (94.0 to 98.2) | 78.0 (73.2 to 82.3) |
| Serogroup Y | 49.9 (44.5 to 55.2) | 35.0 (29.9 to 40.3) |
| Serogroup W | 31.7 (26.9 to 36.9) | 14.5 (10.9 to 18.6) |
Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the hSBA and the results were expressed as geometric mean titers.
| titer | Group 1: MenACYW Conjugate Vaccine | Group 2: Nimenrix® Vaccine |
|---|---|---|
| Serogroup A: Month 6 | 20.8 (16.9 to 25.6) | 26.4 (21.3 to 32.9) |
| Serogroup A: Month 7 | 170 (143 to 202) | 203 (168 to 246) |
| Serogroup C: Month 6 | 227 (197 to 263) | 29.6 (25.1 to 34.9) |
| Serogroup C: Month 7 | 1112 (986 to 1253) | 302 (258 to 355) |
| Serogroup Y: Month 6 | 60.0 (53.1 to 67.8) | 23.7 (20.8 to 27.0) |
| Serogroup Y: Month 7 | 289 (259 to 323) | 268 (237 to 303) |
| Serogroup W: Month 6 | 45.5 (39.5 to 52.3) | 26.1 (22.5 to 30.4) |
| Serogroup W: Month 7 | 275 (240 to 316) | 299 (258 to 345) |
Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the hSBA. Participants with hSBA titers \>= 1:4 and \>= 1:8 were analyzed. Percentages are rounded to the nearest tenth.
| percentage of participants | Group 1: MenACYW Conjugate Vaccine | Group 2: Nimenrix® Vaccine |
|---|---|---|
| Serogroup A: >=1:4; Month 6 | 85.3 (80.6 to 89.2) | 86.2 (81.5 to 90.1) |
| Serogroup A: >=1:4; Month 7 | 98.3 (96.0 to 99.4) | 97.1 (94.3 to 98.7) |
| Serogroup A: >=1:8; Month 6 | 71.0 (65.3 to 76.2) | 76.2 (70.7 to 81.2) |
| Serogroup A: >=1:8; Month 7 | 96.2 (93.2 to 98.1) | 95.6 (92.4 to 97.7) |
| Serogroup C: >=1:4; Month 6 | 99.7 (98.1 to 100) | 93.1 (89.4 to 95.8) |
| Serogroup C: >=1:4; Month 7 | 100 (98.7 to 100) | 98.9 (96.9 to 99.8) |
| Serogroup C: >=1:8; Month 6 | 99.7 (98.1 to 100) | 86.5 (81.9 to 90.3) |
| Serogroup C: >=1:8; Month 7 | 100 (98.7 to 100) | 98.2 (95.9 to 99.4) |
| Serogroup Y: >=1:4; Month 6 | 99.3 (97.5 to 99.9) | 96.1 (93.1 to 98.0) |
| Serogroup Y: >=1:4; Month 7 | 100 (98.8 to 100) | 100 (98.7 to 100) |
| Serogroup Y: >=1:8; Month 6 | 98.3 (96.0 to 99.4) | 90.0 (85.9 to 93.3) |
| Serogroup Y: >=1:8; Month 7 | 99.7 (98.2 to 100) | 99.3 (97.5 to 99.9) |
| Serogroup W: >=1:4; Month 6 | 97.9 (95.6 to 99.2) | 94.6 (91.2 to 96.9) |
| Serogroup W: >=1:4; Month 7 | 98.0 (95.7 to 99.3) | 99.7 (98.1 to 100) |
| Serogroup W: >=1:8; Month 6 | 93.4 (90.0 to 96.0) | 89.5 (85.3 to 92.9) |
| Serogroup W: >=1:8; Month 7 | 98.0 (95.7 to 99.3) | 99.0 (97.0 to 99.8) |
Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay that utilized hSBA. Participants with hSBA titers \>= 4-fold increase from dose 2 (pre-booster dose) were analyzed. Percentages are rounded to the nearest tenth.
| percentage of participants | Group 1: MenACYW Conjugate Vaccine | Group 2: Nimenrix® Vaccine |
|---|---|---|
| Serogroup A | 70.2 (64.3 to 75.6) | 72.9 (67.0 to 78.3) |
| Serogroup C | 69.1 (63.3 to 74.5) | 86.6 (81.9 to 90.4) |
| Serogroup Y | 68.6 (62.9 to 74.0) | 91.0 (87.1 to 94.1) |
| Serogroup W | 78.1 (72.9 to 82.8) | 88.4 (84.0 to 91.9) |
Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the hSBA. hSBA vaccine seroresponse was defined for a participant with a pre-vaccination (pre-dose 2: booster dose) titer \<1:8, as a post-vaccination (post-dose 2: booster dose) titer of \>=1:16 and for a participant with a pre-vaccination titer (pre-dose 2: booster dose) \>=1:8, as a post-vaccination titer (post-dose 2: booster dose) that is at least 4-fold greater than the pre-vaccination titer (pre-dose 2: booster dose). Percentages are rounded to the nearest tenth. Percentages are rounded to the nearest tenth.
| percentage of participants | Group 1: MenACYW Conjugate Vaccine | Group 2: Nimenrix® Vaccine |
|---|---|---|
| Serogroup A | 69.8 (63.9 to 75.3) | 72.5 (66.6 to 77.9) |
| Serogroup C | 69.1 (63.3 to 74.5) | 85.8 (81.1 to 89.8) |
| Serogroup Y | 68.6 (62.9 to 74.0) | 91.0 (87.1 to 94.1) |
| Serogroup W | 77.8 (72.5 to 82.4) | 88.4 (84.0 to 91.9) |
Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the hSBA and the results were expressed as geometric mean titers.
| titer | Group 1: MenACYW Conjugate Vaccine | Group 2: Nimenrix® Vaccine |
|---|---|---|
| Serogroup A: Day 1 | 6.62 (5.27 to 8.31) | 6.82 (5.36 to 8.67) |
| Serogroup A: Month 7 | 170 (143 to 202) | 203 (168 to 246) |
| Serogroup C: Day 1 | 2.97 (2.63 to 3.36) | 2.80 (2.51 to 3.12) |
| Serogroup C: Month 7 | 1112 (986 to 1253) | 302 (258 to 355) |
| Serogroup Y: Day 1 | 2.06 (2.01 to 2.12) | 2.11 (2.03 to 2.20) |
| Serogroup Y: Month 7 | 289 (259 to 323) | 268 (237 to 303) |
| Serogroup W: Day 1 | 2.06 (2.01 to 2.11) | 2.15 (2.03 to 2.28) |
| Serogroup W: Month 7 | 275 (240 to 316) | 299 (258 to 345) |
Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the hSBA. Participants with hSBA titers \>= 1:4 and \>= 1:8 were analyzed. Percentages are rounded to the nearest tenth.
| percentage of participants | Group 1: MenACYW Conjugate Vaccine | Group 2: Nimenrix® Vaccine |
|---|---|---|
| Serogroup A: >=1:4; Day 1 | 37.0 (31.4 to 42.8) | 36.0 (30.3 to 41.9) |
| Serogroup A: >=1:4; Month 7 | 98.3 (96.0 to 99.4) | 97.1 (94.3 to 98.7) |
| Serogroup A: >=1:8; Day 1 | 26.4 (21.4 to 31.8) | 26.6 (21.5 to 32.2) |
| Serogroup A: >=1:8; Month 7 | 96.2 (93.2 to 98.1) | 95.6 (92.4 to 97.7) |
| Serogroup C: >=1:4; Day 1 | 16.7 (12.6 to 21.6) | 16.5 (12.3 to 21.4) |
| Serogroup C: >=1:4; Month 7 | 100 (98.7 to 100) | 98.9 (96.9 to 99.8) |
| Serogroup C: >=1:8; Day 1 | 12.9 (9.2 to 17.3) | 11.0 (7.5 to 15.3) |
| Serogroup C: >=1:8; Month 7 | 100 (98.7 to 100) | 98.2 (95.9 to 99.4) |
| Serogroup Y: >=1:4; Day 1 | 2.1 (0.8 to 4.4) | 3.3 (1.5 to 6.1) |
| Serogroup Y: >=1:4; Month 7 | 100 (98.8 to 100) | 100 (98.7 to 100) |
| Serogroup Y: >=1:8; Day 1 | 1.4 (0.4 to 3.5) | 2.5 (1.0 to 5.2) |
| Serogroup Y: >=1:8; Month 7 | 99.7 (98.2 to 100) | 99.3 (97.5 to 99.9) |
| Serogroup W: >=1:4; Day 1 | 2.4 (1.0 to 4.9) | 4.0 (2.0 to 7.0) |
| Serogroup W: >=1:4; Month 7 | 98.0 (95.7 to 99.3) | 99.7 (98.1 to 100) |
| Serogroup W: >=1:8; Day 1 | 1.0 (0.2 to 3.0) | 1.4 (0.4 to 3.7) |
| Serogroup W: >=1:8; Month 7 | 98.0 (95.7 to 99.3) | 99.0 (97.0 to 99.8) |
Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the hSBA. Participants with hSBA titers \>= 4-fold increase from baseline (pre-vaccination) were analyzed. Percentages are rounded to the nearest tenth.
| percentage of participants | Group 1: MenACYW Conjugate Vaccine | Group 2: Nimenrix® Vaccine |
|---|---|---|
| Serogroup A | 81.5 (76.3 to 85.9) | 79.6 (74.2 to 84.3) |
| Serogroup C | 98.9 (96.8 to 99.8) | 96.6 (93.6 to 98.4) |
| Serogroup Y | 99.0 (97.0 to 99.8) | 98.9 (96.8 to 99.8) |
| Serogroup W | 97.9 (95.5 to 99.2) | 98.2 (95.8 to 99.4) |
Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the rSBA and the results were expressed as geometric mean titers.
| titer | Group 1: MenACYW Conjugate Vaccine | Group 2: Nimenrix® Vaccine |
|---|---|---|
| Serogroup A: Day 1 | 2.30 (1.89 to 2.79) | 2.58 (2.02 to 3.29) |
| Serogroup A: Day 31 | 162 (89.2 to 293) | 926 (630 to 1362) |
| Serogroup C: Day 1 | 2.11 (1.89 to 2.36) | 2.02 (1.98 to 2.05) |
| Serogroup C: Day 31 | 1195 (913 to 1563) | 179 (126 to 253) |
| Serogroup Y: Day 1 | 5.33 (3.48 to 8.15) | 6.26 (3.99 to 9.82) |
| Serogroup Y: Day 31 | 602 (405 to 895) | 576 (412 to 804) |
| Serogroup W: Day 1 | 2.21 (1.91 to 2.57) | 2.13 (1.88 to 2.40) |
| Serogroup W: Day 31 | 1312 (902 to 1909) | 475 (299 to 753) |
Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the rSBA. Participants with rSBA titers \>= 1:8 and \>= 1:128 were analyzed. Percentages are rounded to the nearest tenth.
| percentage of participants | Group 1: MenACYW Conjugate Vaccine | Group 2: Nimenrix® Vaccine |
|---|---|---|
| Serogroup A: >=1:8; Day 1 | 2.7 (0.3 to 9.3) | 5.1 (1.4 to 12.5) |
| Serogroup A: >=1:8; Day 31 | 82.5 (72.4 to 90.1) | 97.6 (91.6 to 99.7) |
| Serogroup A: >=1:128; Day 1 | 2.7 (0.3 to 9.3) | 5.1 (1.4 to 12.5) |
| Serogroup A: >=1:128; Day 31 | 63.8 (52.2 to 74.2) | 90.4 (81.9 to 95.7) |
| Serogroup C: >=1:8; Day 1 | 1.3 (0 to 7.2) | 0 (0 to 4.6) |
| Serogroup C: >=1:8; Day 31 | 100 (95.5 to 100) | 94.0 (86.5 to 98.0) |
| Serogroup C: >=1:128; Day 1 | 1.3 (0 to 7.2) | 0 (0 to 4.6) |
| Serogroup C: >=1:128; Day 31 | 98.8 (93.3 to 100) | 75.9 (65.3 to 84.6) |
| Serogroup Y: >=1:8; Day 1 | 24.0 (14.9 to 35.3) | 26.6 (17.3 to 37.7) |
| Serogroup Y: >=1:8; Day 31 | 95.1 (87.8 to 98.6) | 96.4 (89.8 to 99.2) |
| Serogroup Y: >=1:128; Day 1 | 14.7 (7.6 to 24.7) | 17.7 (10.0 to 27.9) |
| Serogroup Y: >=1:128; Day 31 | 91.4 (83.0 to 96.5) | 96.4 (89.8 to 99.2) |
| Serogroup W: >=1:8; Day 1 | 2.7 (0.3 to 9.3) | 1.3 (0 to 6.9) |
| Serogroup W: >=1:8; Day 31 | 100 (95.5 to 100) | 92.8 (84.9 to 97.3) |
| Serogroup W: >=1:128; Day 1 | 1.3 (0 to 7.2) | 1.3 (0 to 6.9) |
| Serogroup W: >=1:128; Day 31 | 100 (95.5 to 100) | 90.4 (81.9 to 95.7) |
Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the rSBA. Participants with rSBA titers \>= 4-fold increase from baseline (pre-vaccination) were analyzed. Percentages are rounded to the nearest tenth.
| percentage of participants | Group 1: MenACYW Conjugate Vaccine | Group 2: Nimenrix® Vaccine |
|---|---|---|
| Serogroup A | 78.4 (67.3 to 87.1) | 92.4 (84.2 to 97.2) |
| Serogroup C | 100 (95.2 to 100) | 93.7 (85.8 to 97.9) |
| Serogroup Y | 85.3 (75.3 to 92.4) | 82.3 (72.1 to 90.0) |
| Serogroup W | 100 (95.2 to 100) | 92.4 (84.2 to 97.2) |
Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the rSBA. rSBA vaccine seroresponse was defined for a participant with a pre-vaccination (pre-dose 1: priming dose) titer \<1:8, as a post-vaccination titer (post-dose 2: priming dose) of \>=1:32 and for a participant with a pre-vaccination titer (pre-dose 1: priming dose) \>=1:8, as a post-vaccination (post-dose 2: priming dose) titer that is at least 4-fold greater than the pre-vaccination (pre-dose 1: priming dose) titer. Percentages are rounded to the nearest tenth. Percentages are rounded to the nearest tenth.
| percentage of participants | Group 1: MenACYW Conjugate Vaccine | Group 2: Nimenrix® Vaccine |
|---|---|---|
| Serogroup A | 63.5 (51.5 to 74.4) | 92.4 (84.2 to 97.2) |
| Serogroup C | 98.7 (92.8 to 100) | 92.4 (84.2 to 97.2) |
| Serogroup Y | 85.3 (75.3 to 92.4) | 82.3 (72.1 to 90.0) |
| Serogroup W | 100 (95.2 to 100) | 92.4 (84.2 to 97.2) |
Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the rSBA and the results were expressed as geometric mean titers.
| titer | Group 1: MenACYW Conjugate Vaccine | Group 2: Nimenrix® Vaccine |
|---|---|---|
| Serogroup A: Month 6 | 42.7 (20.6 to 88.6) | 67.2 (35.1 to 129) |
| Serogroup A: Month 7 | 1616 (1274 to 2049) | 1827 (1431 to 2332) |
| Serogroup C: Month 6 | 209 (136 to 320) | 17.1 (11.4 to 25.7) |
| Serogroup C: Month 7 | 1819 (1376 to 2404) | 473 (345 to 649) |
| Serogroup Y: Month 6 | 151 (100 to 227) | 90.5 (57.9 to 142) |
| Serogroup Y: Month 7 | 943 (737 to 1207) | 882 (665 to 1169) |
| Serogroup W: Month 6 | 136 (89.1 to 207) | 53.3 (34.1 to 83.3) |
| Serogroup W: Month 7 | 1530 (1176 to 1989) | 1015 (767 to 1343) |
Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the rSBA. Participants with rSBA titers \>= 1:8 and \>= 1:128 were analyzed. Percentages are rounded to the nearest tenth.
| percentage of participants | Group 1: MenACYW Conjugate Vaccine | Group 2: Nimenrix® Vaccine |
|---|---|---|
| Serogroup A: >=1:8; Month 6 | 55.4 (42.5 to 67.7) | 64.8 (52.5 to 75.8) |
| Serogroup A: >=1:8; Month 7 | 100 (95.3 to 100) | 100 (95.4 to 100) |
| Serogroup A: >=1:128; Month 6 | 49.2 (36.6 to 61.9) | 56.3 (44.0 to 68.1) |
| Serogroup A: >=1:128; Month 7 | 100 (95.3 to 100) | 98.7 (93.1 to 100) |
| Serogroup C: >=1:8; Month 6 | 94.1 (85.6 to 98.4) | 68.1 (56.0 to 78.6) |
| Serogroup C: >=1:8; Month 7 | 100 (95.3 to 100) | 98.7 (93.1 to 100) |
| Serogroup C: >=1:128; Month 6 | 77.9 (66.2 to 87.1) | 19.4 (11.1 to 30.5) |
| Serogroup C: >=1:128; Month 7 | 100 (95.3 to 100) | 92.4 (84.2 to 97.2) |
| Serogroup Y: >=1:8; Month 6 | 92.6 (83.7 to 97.6) | 88.6 (78.7 to 94.9) |
| Serogroup Y: >=1:8; Month 7 | 100 (95.3 to 100) | 98.7 (93.1 to 100) |
| Serogroup Y: >=1:128; Month 6 | 73.5 (61.4 to 83.5) | 57.1 (44.7 to 68.9) |
| Serogroup Y: >=1:128; Month 7 | 98.7 (92.9 to 100) | 97.5 (91.2 to 99.7) |
| Serogroup W: >=1:8; Month 6 | 92.8 (83.9 to 97.6) | 80.6 (69.5 to 88.9) |
| Serogroup W: >=1:8; Month 7 | 100 (95.3 to 100) | 100 (95.4 to 100) |
| Serogroup W: >=1:128; Month 6 | 68.1 (55.8 to 78.8) | 52.8 (40.7 to 64.7) |
| Serogroup W: >=1:128; Month 7 | 100 (95.3 to 100) | 96.2 (89.3 to 99.2) |
Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the rSBA. Participants with rSBA titers \>= 4-fold increase from dose 2 (pre-booster dose) were analyzed. Percentages are rounded to the nearest tenth.
| percentage of participants | Group 1: MenACYW Conjugate Vaccine | Group 2: Nimenrix® Vaccine |
|---|---|---|
| Serogroup A | 80.0 (68.2 to 88.9) | 77.5 (66.0 to 86.5) |
| Serogroup C | 80.9 (69.5 to 89.4) | 88.9 (79.3 to 95.1) |
| Serogroup Y | 67.6 (55.2 to 78.5) | 75.7 (64.0 to 85.2) |
| Serogroup W | 89.9 (80.2 to 95.8) | 87.5 (77.6 to 94.1) |
Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the rSBA. rSBA vaccine seroresponse was defined for a participant with a pre-vaccination (pre-dose 2: booster dose) titer \<1:8 as a post-vaccination (post-dose 2: booster dose) titer of \>=1:32 and for a participant with a pre-vaccination (pre-dose 2: booster dose) titer \>=1:8 as a post-vaccination (post-dose 2: booster dose) titer that is at least 4-fold greater than the pre-vaccination (pre-dose 2: booster dose) titer. Percentages are rounded to the nearest tenth.
| percentage of participants | Group 1: MenACYW Conjugate Vaccine | Group 2: Nimenrix® Vaccine |
|---|---|---|
| Serogroup A | 80.0 (68.2 to 88.9) | 77.5 (66.0 to 86.5) |
| Serogroup C | 80.9 (69.5 to 89.4) | 87.5 (77.6 to 94.1) |
| Serogroup Y | 67.6 (55.2 to 78.5) | 75.7 (64.0 to 85.2) |
| Serogroup W | 89.9 (80.2 to 95.8) | 87.5 (77.6 to 94.1) |
Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the rSBA and the results were expressed as geometric mean titers.
| titer | Group 1: MenACYW Conjugate Vaccine | Group 2: Nimenrix® Vaccine |
|---|---|---|
| Serogroup A: Day 1 | 2.34 (1.88 to 2.90) | 2.47 (1.94 to 3.15) |
| Serogroup A: Month 7 | 1616 (1274 to 2049) | 1827 (1431 to 2332) |
| Serogroup C: Day 1 | 2.13 (1.88 to 2.41) | 2.02 (1.98 to 2.06) |
| Serogroup C: Month 7 | 1819 (1376 to 2404) | 473 (345 to 649) |
| Serogroup Y: Day 1 | 4.72 (3.06 to 7.29) | 5.24 (3.37 to 8.14) |
| Serogroup Y: Month 7 | 943 (737 to 1207) | 882 (665 to 1169) |
| Serogroup W: Day 1 | 2.08 (1.92 to 2.26) | 2.00 (NA to NA) |
| Serogroup W: Month 7 | 1530 (1176 to 1989) | 1015 (767 to 1343) |
Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the rSBA. Participants with rSBA titers \>= 1:8 and \>= 1:128 were analyzed. Percentages are rounded to the nearest tenth.
| percentage of participants | Group 1: MenACYW Conjugate Vaccine | Group 2: Nimenrix® Vaccine |
|---|---|---|
| Serogroup A: >=1:8; Day 1 | 3.0 (0.4 to 10.4) | 4.2 (0.9 to 11.7) |
| Serogroup A: >=1:8; Month 7 | 100 (95.3 to 100) | 100 (95.4 to 100) |
| Serogroup A: >=1:128; Day 1 | 3.0 (0.4 to 10.4) | 4.2 (0.9 to 11.7) |
| Serogroup A: >=1:128; Month 7 | 100 (95.3 to 100) | 98.7 (93.1 to 100) |
| Serogroup C: >=1:8; Day 1 | 1.5 (0 to 8.0) | 0 (0 to 5.0) |
| Serogroup C: >=1:8; Month 7 | 100 (95.3 to 100) | 98.7 (93.1 to 100) |
| Serogroup C: >=1:128; Day 1 | 1.5 (0 to 8.0) | 0 (0 to 5.0) |
| Serogroup C: >=1:128; Month 7 | 100 (95.3 to 100) | 92.4 (84.2 to 97.2) |
| Serogroup Y: >=1:8; Day 1 | 20.9 (11.9 to 32.6) | 23.6 (14.4 to 35.1) |
| Serogroup Y: >=1:8; Month 7 | 100 (95.3 to 100) | 98.7 (93.1 to 100) |
| Serogroup Y: >=1:128; Day 1 | 11.9 (5.3 to 22.2) | 15.3 (7.9 to 25.7) |
| Serogroup Y: >=1:128; Month 7 | 98.7 (92.9 to 100) | 97.5 (91.2 to 99.7) |
| Serogroup W: >=1:8; Day 1 | 1.5 (0 to 8.0) | 0 (0 to 5.0) |
| Serogroup W: >=1:8; Month 7 | 100 (95.3 to 100) | 100 (95.4 to 100) |
| Serogroup W: >=1:128; Day 1 | 0 (0 to 5.4) | 0 (0 to 5.0) |
| Serogroup W: >=1:128; Month 7 | 100 (95.3 to 100) | 96.2 (89.3 to 99.2) |
Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the rSBA. Participants with rSBA titers \>= 4-fold increase from baseline (pre-vaccination) were analyzed. Percentages are rounded to the nearest tenth.
| percentage of participants | Group 1: MenACYW Conjugate Vaccine | Group 2: Nimenrix® Vaccine |
|---|---|---|
| Serogroup A | 98.5 (92.0 to 100) | 98.6 (92.5 to 100) |
| Serogroup C | 100 (94.6 to 100) | 97.2 (90.3 to 99.7) |
| Serogroup Y | 92.5 (83.4 to 97.5) | 91.7 (82.7 to 96.9) |
| Serogroup W | 100 (94.6 to 100) | 100 (95.0 to 100) |
Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the rSBA. rSBA vaccine seroresponse was defined for a participant with a pre-vaccination (pre-dose 1: priming dose) titer \<1:8, as a post-vaccination (post-dose 2: booster dose) titer of \>=1:32 and for a participant with a pre-vaccination (pre-dose 1: priming dose) titer \>=1:8, as a post-vaccination (post-dose 2: booster dose) titer that is at least 4-fold greater than the pre-vaccination (pre-dose 1: priming dose) titer. Percentages are rounded to the nearest tenth.
| percentage of participants | Group 1: MenACYW Conjugate Vaccine | Group 2: Nimenrix® Vaccine |
|---|---|---|
| Serogroup A | 98.5 (92.0 to 100) | 98.6 (92.5 to 100) |
| Serogroup C | 100 (94.6 to 100) | 95.8 (88.3 to 99.1) |
| Serogroup Y | 92.5 (83.4 to 97.5) | 91.7 (82.7 to 96.9) |
| Serogroup W | 100 (94.6 to 100) | 100 (95.0 to 100) |
An unsolicited AE was an observed AE that did not fulfill the conditions of solicited reactions, i.e., pre-listed in the case report form (CRF) in terms of diagnosis and onset window post-vaccination.
| Participants | Group 1: MenACYW Conjugate Vaccine | Group 2: Nimenrix® Vaccine |
|---|---|---|
| Number of Participants With Immediate Unsolicited Systemic Adverse Events (AEs) | 2 | 1 |
A solicited reaction was an "expected" adverse reaction (AR) (sign or symptom) observed and reported under the conditions (nature and onset) pre-listed in the protocol and CRF. An injection site reaction was an AR at and around the injection site. Solicited systemic reactions were systemic AEs observed and reported under the conditions (nature and onset) pre-listed in the protocol and CRF.
| Participants | Group 1: MenACYW Conjugate Vaccine | Group 2: Nimenrix® Vaccine |
|---|---|---|
| Solicited injection site reaction | 234 | 245 |
| Solicited systemic reaction | 312 | 326 |
An unsolicited AE was an observed AE that did not fulfill the conditions of solicited reactions, i.e., pre-listed in the CRF in terms of diagnosis and/or onset window post-vaccination.
| Participants | Group 1: MenACYW Conjugate Vaccine | Group 2: Nimenrix® Vaccine |
|---|---|---|
| Number of Participants With Unsolicited Adverse Events | 246 | 243 |
An SAE was any AE that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event. An AESI (serious or non-serious) was defined as one of scientific and medical concern specific to the Sponsor's study intervention or program, for which ongoing monitoring and rapid communication by the investigator to the Sponsor could be appropriate.
| Participants | Group 1: MenACYW Conjugate Vaccine | Group 2: Nimenrix® Vaccine |
|---|---|---|
| SAEs | 21 | 20 |
| AESIs | 3 | 2 |
Collected over AEs, SAEs, and all-cause mortality (deaths) were collected from vaccination (Day 1) up to 30 days post last vaccination, approximately 7 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 1: MenACYW Conjugate Vaccine | 0/417 (0%) | 21/417 (5%) | 347/417 (83.2%) |
| Group 2: Nimenrix® Vaccine | 1/412 (0.2%) | 20/412 (4.9%) | 370/412 (89.8%) |
| Event | Group 1: MenACYW Conjugate Vaccine | Group 2: Nimenrix® Vaccine |
|---|---|---|
| PneumoniaInfections and infestations | 4/417 | 3/412 |
| Febrile ConvulsionNervous system disorders | 3/417 | 1/412 |
| ConcussionInjury, poisoning and procedural complications | 1/417 | 2/412 |
| BronchitisInfections and infestations | 2/417 | 1/412 |
| Upper Respiratory Tract InfectionInfections and infestations | 2/417 | 0/412 |
| Bronchitis ViralInfections and infestations | 0/417 | 1/412 |
| Covid-19Infections and infestations | 1/417 | 1/412 |
| Exanthema SubitumInfections and infestations | 1/417 | 1/412 |
| LaryngitisInfections and infestations | 1/417 | 1/412 |
| Parainfluenzae Virus InfectionInfections and infestations | 0/417 | 1/412 |
| Event | Group 1: MenACYW Conjugate Vaccine | Group 2: Nimenrix® Vaccine |
|---|---|---|
| IrritabilityPsychiatric disorders | 253/417 | 263/412 |
| CryingGeneral disorders | 228/417 | 240/412 |
| Injection Site ErythemaGeneral disorders | 160/417 | 182/412 |
| SomnolenceNervous system disorders | 149/417 | 175/412 |
| Injection Site PainGeneral disorders | 159/417 | 155/412 |
| Decreased AppetiteMetabolism and nutrition disorders | 141/417 | 157/412 |
| Injection Site SwellingGeneral disorders | 89/417 | 97/412 |
| PyrexiaGeneral disorders | 86/417 | 86/412 |
| VomitingGastrointestinal disorders | 86/417 | 70/412 |
| Upper Respiratory Tract InfectionInfections and infestations | 57/417 | 53/412 |
All randomized participants
| Age, Continuous(months) | Group 1: MenACYW Conjugate Vaccine | Group 2: Nimenrix® Vaccine | Total |
|---|---|---|---|
| Mean | 6.5 ± 0.50 | 6.5 ± 0.50 | 6.5 ± 0.50 |
| Sex: Female, Male(Participants) | Group 1: MenACYW Conjugate Vaccine | Group 2: Nimenrix® Vaccine | Total |
|---|---|---|---|
| Female | 200 | 182 | 382 |
| Male | 222 | 236 | 458 |
| Race/Ethnicity, Customized(Participants) | Group 1: MenACYW Conjugate Vaccine | Group 2: Nimenrix® Vaccine | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 2 | 7 | 9 |
| Black or African American | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| White | 417 | 407 | 824 |
| Multiple | 1 | 2 | 3 |
| Not Reported | 1 | 0 | 1 |
| Unknown | 1 | 1 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Mar 2024 to primary completion in Nov 2025, 19 months.
Results were first posted in Oct 2026, 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sanofi Pasteur, a Sanofi Company →